Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST

1 Nov 2011

Abstract excerpt

Gastrointestinal stromal tumors (GISTs), defined by the presence of constitutively activated KIT, are the most common gastrointestinal mesenchymal malignancies. This observation has been successfully exploited in clinical trials of Gleevec (also known as imatinib mesylate, STI-571) for patients with unresectable and/or metastatic GISTs. The biological mechanisms of Gleevec as well as its downstream molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastric Cancer Management and Outcomes
Share to Gastrointestinal Tumor Research and Treatment
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12939459
DOI: 10.1158/1535-7163.mct-11-0709

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bench to Bedside and Back Again: Personalizing Treatment for Patients with GISTPMID 12939459Read ↗

Novel treatment targets in sarcoma: more than just the GIST.Semantic proximity Read ↗

Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.Semantic proximity Read ↗

Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.Semantic proximity Read ↗

Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.Semantic proximity Read ↗

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.Semantic proximity Read ↗

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Semantic proximity Read ↗

Precision medicine in gastrointestinal stromal tumors.Semantic proximity Read ↗

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.Semantic proximity Read ↗

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal TumorSemantic proximity Read ↗

Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS).Semantic proximity Read ↗

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment.Semantic proximity Read ↗

A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.